Abstract
Refractory acute myeloid leukemia (R-AML), defined as primary resistance to induction chemotherapy, early relapse (within 6-12 months from remission), and second or subsequent relapse, is typically a multidrugresistant illness, for which effective treatment is presently lacking. We have treated R-AML patients with a combination of intermediatedose ara-C, carboplatin and either mitoxantrone or idarubicin in a cross-over design, obtaining an encouraging response rate (46%) in a small group of 13 R-AML patients who were given an amended, low-toxicity regimen [1]. Five more patients were treated with a similar carboplatin-containing schedule delivered in a sequential manner, but only one remission was achieved, to an overall response rate of 33% (6/18). This result prompted a further change in retreatment strategy. In R-AML, clinical multidrug resistance is often associated with functional overexpression of the MDR1 drug efflux machinery and/or other mechanisms such as LRP (lung-related protein) and MRP (multidrug resistance-associated protein) [2-11]. Theoretically, in view of the high incidence of MDR1 activation in R-AML and its adverse clinical significance, functional MDR1 inhibition with cyclosporin A (CsA), verapamil, tamoxifen, PSC 833, quinine [12-19] or the use of drugs scarcely (Idarubicin=IDR) or not (high-dose ara-C=HiDAC, carboplatin) MDR1-sensitive could underlie therapeutic improvement. In preclinical in vitrostudies on a MDR1+ human leukemic cell line [20,21], we found that both cellular uptake and pro-apoptotic effects of IDR used at therapeutic concentration (50-100 ng/ml, corresponding to the ranges of peak plasma level obtainable after rapid intravenous administration of IDR 10-12 mg/m2) were significantly increased by co-incubation with CsA 1500 ng/ml. Interestingly, CsA enhanced IDR-related cytotoxicity only in the early phase of IDR-blast cell interaction while, contrary to daunorubicin, 12-hour IDR retention by blast cells was not modified by CsA. The study conclusion was that both cellular uptake of and related biologic effects from IDR can be upregulated by CsA in MDR1+ cells but, partly because IDR is highly lypophilic and partly because it is less vulnerable to MDR1, this effect does not require a prolonged CsA exposure. On this basis we initiated a new clinical study, using CsA and aiming to determine the upper IDR concentration tolerated by patients with R-AML. This new sequential regimen included HiDAC 3 g/m2 every 12 hours for two consecutive days followed by IDR 12.5 mg/m2 as starting dose level (both drugs were given for two times on days 1-3 and 8-10) together with CsA 6 mg/kg over 1 hour and then 7.5 mg/kg over 11 hours according to the List schedule [22]. IDR was delivered 4 hours after starting CsA. The three-day sequence was repeated on days 8-10. Recombinanat human granulocyte colony-stimulating factor (G-CSF) was administered from day 11 until response evaluation. We report the therapeutic results obtained in the first 10 patients, who received IDR from 12.5 to 17.5 mg/m2/dose.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bassan R, Lerede T, Buelli M et al (1998) A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute acute myeloid leukemia. Haematologica 83:422–427.
Filipits M, Pohl G, Stranzl T et al (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91:1508–1513.
Del Poeta G, Stasi R, Aronica G et al (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87:1997–2004.
List AF, Spier CS, Grogan TM et al (1996) Overex-pression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464–2469.
te Boekhorst P, Löwenberg B, van Kapel J et al (1995) Multidrug resistance cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9:1025–1031.
Nüssler V, Pelka-Fleischer R, Zwierzina H et al (1996) P-glycoprotein expression in patients with acute leukemia—clinical relevance. Leukemia 10 (Suppl 3):S23–S31.
Leith CP, Chen IM, Kopecky KJ et al (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant Mdr /efflux+ and MDRl+/efflux-cases. Blood 86: 2329–2342.
Ross DD, Doyle LA, Schiffer CA et al (1996) Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 10:48–55.
Guerci A, Merlin JL, Missoum N et al (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147–2153.
Campos L, Guyotat D, Archimbaud E et al (1992) Clinical significance of multidrug resistance P-gly-coprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473–476.
Schneider E, Cowan KN, Bader H et al (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186–193.
Wattel E, Solary E, Hecquet B et al (1998) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of randomized study. Br J Haematol 102:1015–1024.
Kornblau SM, Estey E, Madden T et al (1997) Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796–1802.
Solary E, Caillot D, Chauffert B et al (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730–1736.
Solary E, Witz B, Caillot D et al (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88:1198–1205.
Berman E, McBride M, Lin S et al (1995) Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9:1631–1637.
Bartlett NL, Lum BL, Fisher G A et al (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835–842.
Ross DD, Wooten PJ, Tong Y et al (1994) Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporine A and cremophor EL. Blood 83:1337–1347.
Ross DD, Wooten PJ, Sridhara R et al (1993) Enhancement of daunorubicin accumulation, retention, and cytotoxity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82: 1288–1299.
Chiodini B, Bassan R, Borleri G et al (1998) Idarubicin activity against multidrug-resistant (mdr-l+) cells is increased by cyclosporin A. In: Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds) Acute Leukemias VII. Springer-Verlag Berlin Heidelberg: pp 475–482.
Chiodini B, Bassan R, Barbui T (1999) Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Leuk Lymph ( in press).
List AF, Spier C, Greer J et al (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652–1660.
Liso V, Iacopino P, Awisati G et al (1996) Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 un-selected consecutive patients. Leukemia 10: 1443–1452.
Anderlini P, Ghaddar HM, Smith TL et al (1996) Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 10:964–969.
Kern W, Aul C, Maschmeyer G et al (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with highrisk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049–1055.
Bassan R, Chiodini B, Lerede T et al (1997) The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. Leuk Lymph 26(Suppl l):89–97.
Speth PA, Minderman H, Haanen C (1989) Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 16(Suppl 2): 2–9.
Lehnert M (1996) Clinical multidrug resistance in cancer: a multifactorial problem. J Clin Oncol 32A:912–920.
Damiani D, Michieli M, Ermacora A et al (1998) Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphoblastic leukemia. Leukemia 12:1236–1240.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bassan, R., Lerede, T., Chiodini, B., Rossi, A., Buelli, M., Barbui, T. (2001). Split-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J., Creutzig, U. (eds) Acute Leukemias VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18156-6_71
Download citation
DOI: https://doi.org/10.1007/978-3-642-18156-6_71
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62109-3
Online ISBN: 978-3-642-18156-6
eBook Packages: Springer Book Archive